Philip Romm, MD
Interventional Cardiology · Lawrenceville, GANPI 1760478184
Payments from drug & device makers
Across 481 payments — averaging $107.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$28K
- Amgen$9K
- Boston Scientific$6K
- Penumbra, Inc.$3K
- Johnson & Johnson$635
- Novartis$592
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 57 | $28,387 |
| Amgen | 64 | $8,606 |
| Boston Scientific | 68 | $6,483 |
| Penumbra, Inc. | 7 | $2,712 |
| Johnson & Johnson | 40 | $635 |
| Novartis | 33 | $592 |
| Pfizer | 26 | $475 |
| Amarin Pharma, Inc. | 27 | $389 |
| Esperion Therapeutics, Inc. | 22 | $377 |
| E.r. Squibb & Sons, L.L.C. | 18 | $330 |
| Abiomed | 10 | $302 |
| Boehringer Ingelheim | 12 | $253 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $237 |
| AstraZeneca | 13 | $227 |
| Sanofi-aventis U.S. LLC | 13 | $225 |
| Shockwave Medical, Inc | 4 | $214 |
| Inari Medical, Inc. | 1 | $199 |
| Angiodynamics, Inc. | 2 | $199 |
| Bayer | 5 | $132 |
| Edwards Lifesciences | 3 | $131 |
| Merck | 6 | $115 |
| Regeneron Healthcare Solutions, Inc. | 5 | $109 |
| W. L. Gore & Associates, Inc. | 4 | $107 |
| Arbor Pharmaceuticals, Inc. | 5 | $64 |
| Chiesi USA, Inc. | 3 | $50 |
| Heartflow, Inc. | 2 | $45 |
| Medtronic | 3 | $40 |
| Novo Nordisk | 2 | $35 |
| Lundbeck LLC | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Gilead | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $22 |
| GSK | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Baylis Medical Company Inc | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$51,839 in reported general payments places this provider in the 75th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Lawrenceville
- Henry LibermanLawrenceville$110K
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Amar PatelMarietta$1.8M
- Vivek RajagopalAtlanta$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.